Efficacy

Keytruda (Pembrolizumab) Efficacy in Lymphoma

Keytruda, known generically as pembrolizumab, is a monoclonal antibody that has shown efficacy in treating various types of cancer, including lymphoma. Specifically, it is used to treat classical Hodgkin lymphoma (cHL) after failure of other treatments. Pembrolizumab works by blocking the PD-1 pathway, which cancer cells often exploit to evade the immune system. By inhibiting this pathway, Keytruda helps the immune system to detect and fight cancer cells more effectively.

In clinical trials, pembrolizumab has demonstrated significant efficacy in patients with relapsed or refractory classical Hodgkin lymphoma. The response rates in these studies have been encouraging, with a proportion of patients achieving complete remission. However, the efficacy can vary based on previous treatments and the extent of the disease. Keytruda has been granted approval by regulatory agencies for this indication, reflecting its benefit in this hard-to-treat lymphoma.

Truxima (Rituximab) Efficacy in Lymphoma

Truxima, a biosimilar to the original rituximab, is another monoclonal antibody used in the treatment of lymphoma. Rituximab targets the CD20 antigen on B cells, which is commonly expressed in non-Hodgkin lymphoma (NHL) and some types of Hodgkin lymphoma. By binding to CD20, Truxima helps the immune system to destroy these malignant B cells. It is used for various subtypes of NHL, including follicular lymphoma and diffuse large B-cell lymphoma, often in combination with chemotherapy.

The efficacy of rituximab, and by extension Truxima, has been well established through numerous clinical trials and extensive clinical experience. It has been shown to improve survival rates when used as a first-line treatment and also has a role in maintenance therapy for certain types of NHL. Truxima provides a more cost-effective alternative to the original rituximab while maintaining similar efficacy and safety profiles, making it a valuable option in the management of lymphoma.